Market Closed - Australian S.E. 01:07:52 2024-04-24 am EDT 5-day change 1st Jan Change
0.105 AUD 0.00% Intraday chart for Echo IQ Limited +5.00% -38.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Echo IQ CEO Steps Down; Chairman Named Interim Successor MT
Careteq Appoints CEO; Shares Down 6% MT
Echo IQ Secures R&D Tax Rebate for Fiscal Year 2023 MT
Echo IQ Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Echo IQ Limited Announces the Resignation of Shannon Robinson from the Role of Joint Company Secretary CI
Respiri Signs Deal to Integrate Echo IQ’s Cardiovascular Technology to Remote Monitoring System; Shares Fall 4% MT
Echo IQ Appoints CEO MT
Echo IQ Limited Announces CEO Changes, Effective 29 January 2024 CI
EchoIQ Applies for Patent for Heart Failure Algorithm MT
Echo IQ Secures R&D Tax Rebate for Fiscal Year 2022; Shares Fall 3% MT
Echo IQ Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Echo IQ Signs Deal to Pilot Heart Disease Detection Tool; Shares Jump 7% MT
Echo IQ to Launch Six Modules for Cardiology Platform MT
Echo IQ Completes Enrollment for Clinical Decision Software Study in the US MT
Echo IQ Launches Heart Valve Abnormality Module MT
Echo IQ Secures First Deal to Supply EchoSolv Technology to Australian Hospital; Shares Rise 3% MT
Core Sound Imaging, Inc. and Echo IQ Finalize Integration Agreement for EchoSolv CI
Echo IQ Announces the Appointment of Simon Tolhurst as A Non-Executive Director CI
Echo IQ Appoints Exclusive Sales Agent for EchoSolv for Mid-West Region, US MT
Hydrix Enters Commercial Deal to Sell Heart Disease Detection Platform MT
Australian Bourse to Halt Trading in Echo IQ's Securities MT
Echo IQ Limited Announces Change of Joint Company Secretary CI
Echo IQ Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Echo IQ's Screening Platform Achieves High Diagnostic Rate for Heart Valve Disease MT
Echo Iq Limited Announces Positive Interim Results from Clinical Trial At St Vincent's CI
Chart Echo IQ Limited
More charts
EchoIQ Limited (ECHOiQ) is an Australia-based health and medical technology company. The Company is engaged in the product development, marketing and commercialization of software products and services. It provides cardiac diagnostics technology. The Company has developed cloud-based decision-support software, EchoSolv, powered by artificial intelligence (AI) and machine learning, which aims to provide physicians with a reliable tool to identify patients at-risk of structural heart disease. ECHOiQ’s technology uses AI assisted diagnostics to deliver real-world health solutions. Its screening program uses an AI backed system and access to cardiac big data that identifies patients at risk from aortic stenosis and other forms of structural heart disease. The Company's technology addresses aortic stenosis, heart failure, and mitral and tricuspid regurgitation.
More about the company
  1. Stock Market
  2. Equities
  3. EIQ Stock
  4. News Echo IQ Limited
  5. Houston We Have : Edwards Lifesciences to Fund Houston We Have's Clinical Trial of ECHOiQ’s Technology; Shares Rise 11%